Hello! Welcome to the official website of Betta Pharmaceuticals!
Service Hotline:0571-86130357     Add to Favorites | Online Feedback 中文
新闻中心 / News Center
Several Achievements of Betta Pharmaceuticals Present at WCLC
Form: Department of Medicine   Date: 2017-10-24

    The 18th Session of the World Conference on Lung Cancer (WCLC), sponsored by IASLC, was held in Yokohama recently, which attracted over 7,000 representatives from over 100 countries and regions in the world. Experts and scholars specialized in the fields of surgery, oncology, radiotherapy, respiratory medicine, pathologist, epidemiology, basic research and nursing gathered together, based on the theme of “Synergy to Conquer Lung Cancer”, to communicate with the latest progress of lung cancer research respectively and discuss the solution for this severe disease all around the world. 

    Dr. Tan Fenlai, SVP and CMO of Betta Pharmaceuticals, led the members of Department of Medicine of Betta Pharmaceuticals, to participate in this conference for an in-depth communication with experts and scholars. 


Dr. Tan Fenlai, Prof. Wu Yillong and VP/Director of Clinical Operation of Xcovery Kimberly Harrow Taken a Photo in front of the Poster of eXalt-3 Research 

    12 abstracts submitted by Betta Pharmaceutical were accepted by this conference; besides that Icotinib Hydrochloride has won a worldwide reputation as the core product, Ensartinib (X-396) and BPI-9016, which are under research and development, have also accessed into the vision of international academic circle gradually. The eXalt-3 research, jointly submitted by Betta Pharmaceuticals and Xcovery, has attracted the great responses; Ensartinib has turned into another influential ALK inhibitor highly concerned by the international academic circle. CONVINE, BRAIN and EVIDENCE studies about Icotinib Hydrochloride were mentioned by scholars and experts in the plenary lectures repeatedly. 

    In 2009, Icotinib Hydrochloride was debut at the 13th Session of WCLC, as the emergence of Chinese original drugs and research at the world stage for the first time; in 2011, Academician Sun Yan reported the results of ICOGEN study of Phase III clinical study of Icotinib Hydrochloride at the 14th Session of WCLC; in 2015 and 2016, CONVINCE and BRAIN, two significant Phase III research of Icotinib Hydrochloride after ICOGEN, were accepted by WCLC in the form of oral reporting; Icotinib Hydrochloride-relevant research has provided the abundant evidence of EBM for individualized treatment and clinical diagnosis practice of NSCLC. 22.jpg

Poster Presentation of Icotinib Hydrochloride-related Research at the Conference

    Since the date of its development, Icotinib Hydrochloride has been insisting in the road of academic promotion. So far, there have been 171 pieces of relevant articles and overviews published in international journals and at academic conferences, with an accumulative IF over 400 grades and over 900 times of quotation. Icotinib Hydrochloride will inevitably give rise to a China fever in the international academic circle, along with the emergence of Chinese new drug research and development. 

Prev: An Extraordinary 6-year Journey-The 6th Debut Anniversary Academic Summit of Conmana Held in Guangzhou
Next: Latest Research Results of Conmana Enjoying a Good Fame at CSCO with High Praise of Academician Sun Yan for Betta Pharmaceuticals’ Innovative Development